Tirzepatide dosage chart
5 mg Vial
Tirzepatide is dosed at 2.5 mg–10 mg weekly via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 2.5 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
- Typical weekly range
- 2.5–15 mg once weekly (gradual 4‑week titration steps).
- Easy measuring
- At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U‑100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
Dosing schedule
| Phase | Weekly Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 100 units (1.0 mL) × 1 injection |
| Weeks 5–8 | 5 mg | 100 units (1.0 mL) × 2 injections |
| Weeks 9–12 | 7.5 mg | 100 units (1.0 mL) × 3 injections |
| Weeks 13–16 | 10 mg | 100 units (1.0 mL) × 4 injections |
Reconstitution steps
- 1Draw 2.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake).
- 4Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 5Use within 28 days of reconstitution.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- For multi‑injection doses, use different sites for each injection on the same day.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document weekly dose, date, and injection site to maintain consistency.
- Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them.
How This Works
Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials. Its ~5‑day half‑life enables convenient once‑weekly administration.
Potential Benefits & Side Effects
Observations from clinical trials and published literature.
- Glycemic control: Significant HbA1c reductions in type 2 diabetes trials.
- Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses).
- Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies.
- Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence.
- Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.
- Prioritize protein to preserve lean mass during weight loss.
- Combine resistance training and aerobic activity to support metabolic health.
- Stay hydrated, especially given potential gastrointestinal effects.
- Prioritize sleep and stress management to support adherence and recovery.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy.
- Dispose of needles and syringes in a sharps container immediately after use.
important-note
This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment.
Tirzepatide dosage FAQs
How much bacteriostatic water do you use to reconstitute Tirzepatide?
Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration. for a 5 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What does the Tirzepatide dosing schedule look like?
Weeks 1–4 — 2.5 mg — 100 units (1.0 mL) × 1 injection; Weeks 5–8 — 5 mg — 100 units (1.0 mL) × 2 injections; Weeks 9–12 — 7.5 mg — 100 units (1.0 mL) × 3 injections; Weeks 13–16 — 10 mg — 100 units (1.0 mL) × 4 injections. The full table above lists every step with matching syringe units.
What are the mixing steps for Tirzepatide?
Draw 2.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).
How should reconstituted Tirzepatide be stored?
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days..
How many insulin syringe units equal a Tirzepatide dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is Tirzepatide approved for human use?
No. Tirzepatide is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.